Roche, waving off research failures, commits to Part 3 trials for Parkinson’s drug

The Swiss drugmaker mentioned it was “inspired” by the indicators of effectiveness of the drug, developed by biotech Prothena, confirmed in two earlier research that missed their most important objectives.